Argus Research Maintains Buy on CVS Health, Raises Price Target to $114

Benzinga Newsdesk www.benzinga.com Positive 76.1%

Neg 0% Neu 0% Pos 76.1%

Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.